+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Eczema Therapeutics Market by Treatment Type, Distribution Channel, Product Type, Formulation, End User - Global Forecast to 2030- Product Image
Eczema Therapeutics Market by Treatment Type, Distribution Channel, Product Type, Formulation, End User - Global Forecast to 2030- Product Image
Sale

Eczema Therapeutics Market by Treatment Type, Distribution Channel, Product Type, Formulation, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674454
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Eczema Therapeutics Market grew from USD 7.49 billion in 2024 to USD 8.24 billion in 2025. It is expected to continue growing at a CAGR of 9.67%, reaching USD 13.04 billion by 2030.

Redefining the Eczema Therapeutics Landscape with Strategic Insights

Eczema represents a multifaceted dermatological challenge affecting millions of individuals worldwide, imposing significant clinical, economic, and quality-of-life burdens. As patient populations expand and therapeutic expectations evolve, stakeholders from R&D to payers face mounting pressure to deliver solutions that balance efficacy, safety, and affordability. Recent advances in immunology and molecular biology have unlocked new avenues for targeted intervention, yet the pathway to broad patient access and optimal treatment sequencing remains complex.

This executive summary distills the most critical trends shaping the eczema therapeutics market today. By examining emerging technologies, shifting regulatory landscapes, and evolving patient behaviors, we offer a panoramic view of market forces that will define competitive positioning over the next decade. The insights contained herein synthesize both primary and secondary research to illuminate the interplay between innovation, reimbursement, and commercial strategy.

Designed for decision-makers across pharmaceutical, biotechnology, and healthcare services sectors, this document provides a concise yet comprehensive foundation for strategic planning. It sets the stage for deeper exploration of market dynamics, enabling stakeholders to anticipate disruptions, capitalize on pivotal growth drivers, and mitigate potential headwinds. With clarity and precision, this introduction establishes the context for a detailed journey through the transformative shifts unfolding in eczema therapeutics.

Emerging Forces Reshaping Treatment Paradigms and Patient Outcomes

Over the past five years, breakthroughs in biologics and Janus kinase inhibitors have fundamentally altered the treatment paradigm for moderate-to-severe eczema, moving care from broad-spectrum immunosuppression toward precision immunomodulation. The success of interleukin antagonists has validated the strategy of targeting specific inflammatory pathways, while next-generation JAK inhibitors are rapidly gaining traction due to their oral administration profile and rapid onset of action.

Concurrently, patient-centric models are gaining prominence, leveraging teledermatology platforms, digital adherence tools, and real-world evidence portals to support personalized treatment journeys. The integration of electronic patient-reported outcomes enables clinicians and payers to assess therapeutic value beyond traditional clinical endpoints, fostering a shift toward value-based contracting.

Regulatory agencies are responding by streamlining approval pathways for therapies addressing unmet needs, accelerating the timeline from bench to bedside. Simultaneously, payers are demanding deeper evidence of long-term cost-effectiveness, prompting manufacturers to invest in health-economics studies and innovative pricing arrangements. These convergent forces are poised to reshape competitive advantages, rewarding organizations that can deliver differentiated clinical data, robust patient support services, and flexible commercial models.

Assessing the 2025 United States Tariff Changes and Their Market Implications

The introduction of new tariff structures in the United States for 2025 heralds a period of adjustment for global supply chains in eczema therapeutics. Although many active pharmaceutical ingredients and specialty excipients are sourced internationally, the increased duties on key imports will necessitate strategic procurement realignments. Manufacturers may face higher input costs, compelling them to reevaluate sourcing strategies and localize critical manufacturing steps.

For companies that rely on global contract development and manufacturing organizations, the tariff shift underscores the importance of onshoring or near-shoring capabilities to preserve margin integrity. In contrast, entities with established domestic production infrastructures are likely to gain a competitive edge, able to negotiate more favorable terms with payers and distributors. This realignment will also influence pricing negotiations with pharmacy benefit managers and hospital formularies, as stakeholders seek to contain out-of-pocket expenses for patients.

Moreover, the regulatory scrutiny on import documentation and compliance is expected to intensify, increasing the administrative burden on supply chain teams. Companies proactive in adapting to the new tariff framework by forging strategic alliances with local suppliers and investing in tariff-mitigation technologies will be best positioned to navigate this evolving landscape without compromising market access or patient affordability.

Uncovering Layered Market Segments Driving Therapeutic Adoption

An in-depth look at market segmentation reveals nuanced growth vectors across multiple dimensions. Based on treatment type, therapeutic strategies divide into phototherapy, systemic interventions that include both biologics and Janus kinase inhibitors, and topical modalities encompassing over-the-counter options such as anti-itch lotions, barrier repair creams and emollients as well as prescriptions that span calcineurin inhibitors, corticosteroids and PDE4 inhibitors. Distribution channels extend from hospital pharmacies to online and brick-and-mortar retail outlets, each delivering unique patient engagement opportunities and cost structures.

When the market is analyzed by product type, the dichotomy between over-the-counter preparations and prescription medications highlights distinct adoption drivers, cost considerations and regulatory pathways. Formulation preferences further stratify the landscape, with creams, gels, lotions and ointments catering to varying severity levels and patient lifestyles. Finally, end-user segmentation between adult and pediatric populations underscores the imperative for age-appropriate formulations, tailored dosing regimens and specialized support programs. By synthesizing these layered segments, stakeholders can pinpoint under-served niches, optimize portfolio mixes and align commercial tactics with evolving patient and payer expectations.

Regional Dynamics Informing Strategic Priorities Across Key Markets

Different regions present distinct opportunities and challenges that demand customized strategies. In the Americas, robust reimbursement frameworks for biologics and emerging small molecules have accelerated adoption rates among moderate-to-severe patient cohorts, while strong patent protections continue to attract high levels of R&D investment. In Europe, Middle East & Africa, a mosaic of healthcare systems and variable payer policies necessitates sophisticated market access plans, including local health-economics evaluations and managed entry agreements.

The Asia-Pacific region is characterized by rapid modernization of dermatology clinics and growing patient awareness, yet market growth is tempered by pricing pressures and heterogeneity in regulatory standards. Many countries are implementing centralized procurement programs that prioritize cost containment, challenging manufacturers to demonstrate superior value or pursue tiered pricing models. Across all regions, partnerships with local stakeholders-from advocacy groups to clinical research networks-are proving critical for successful launches and sustained uptake in both urban and rural settings.

Industry Trailblazers Steering Innovation and Competitive Positioning

Leading enterprises are distinguishing themselves through a blend of breakthrough therapies and strategic collaborations. Companies pioneering interleukin inhibitors have secured early mover advantages, underpinned by robust clinical data and extensive real-world evidence initiatives. Simultaneously, developers of oral small molecules are forging partnerships with diagnostic firms to refine patient selection and enhance response rates.

Topical innovation has been driven by specialized dermatology players who leverage novel delivery systems to optimize skin penetration and improve patient adherence. These firms are also expanding into digital health by embedding adherence tracking technologies within packaging. In parallel, major pharmaceutical organizations are pursuing acquisitions to accelerate entry into high-value segments, while advanced biotechnology companies are establishing co-development agreements to share risk and expertise.

Collectively, these strategies underscore a broader industry pivot toward integrated platforms that blend pharmaceutical, digital and service-based offerings. Organizations that can harmonize clinical innovation with agile commercialization models and patient support ecosystems will set new benchmarks for leadership in eczema therapeutics.

Action Steps for Leaders to Capitalize on Emerging Opportunities

Leaders in the eczema therapeutics domain should prioritize the integration of digital patient support tools with clinical offerings to enhance adherence, monitor outcomes and reinforce value-based care models. Allocating resources toward localized manufacturing capabilities and strategic supplier partnerships will mitigate the impact of evolving tariff regimes and optimize margin stability. It is equally essential to invest in health-economics and outcomes research early in the development process to underpin payer negotiations and secure favorable formulary positions.

Strategic alliances with dermatology clinics and advocacy groups can facilitate the collection of real-world evidence, while collaborative pilot programs with payers enable testing of innovative reimbursement structures such as subscription models and outcome-linked contracts. Companies must also explore flexible pricing frameworks that address the affordability gap in diverse markets, balancing premium positioning in developed regions with tiered approaches in cost-sensitive territories.

By aligning R&D priorities with market access imperatives and patient engagement strategies, industry players can build resilient commercial infrastructures capable of navigating regulatory complexities, competitive pressures and shifting healthcare economics. Such a holistic approach will ensure sustained growth and leadership in the dynamic eczema therapeutics arena.

Methodological Rigor Underpinning Comprehensive Market Insights

This research combines a rigorous qualitative and quantitative framework. Primary data were gathered through in-depth interviews with key opinion leaders, dermatologists, payer representatives and industry executives to capture firsthand perspectives on clinical practice patterns and market access dynamics. Secondary sources included peer-reviewed journals, regulatory filings, company presentations and public financial disclosures, ensuring a robust foundation of validated intelligence.

Market segmentation and trend analysis were conducted using proprietary data triangulation techniques, synthesizing disparate datasets to identify convergent insights and emerging inflection points. Regional analyses were enriched by country-level deep dives that examined healthcare infrastructure, reimbursement mechanisms and competitive landscapes. Quality control protocols involved cross-referencing findings against independent third-party databases and expert reviews, affirming the accuracy and relevance of all conclusions.

This methodological rigor underpins the actionable intelligence presented throughout this report, providing stakeholders with confidence in the validity of strategic recommendations, risk assessments and opportunity maps. The comprehensive approach ensures that insights are grounded in both current realities and forward-looking indicators.

Synthesizing Core Findings to Navigate Future Market Realities

Eczema therapeutics is at a crossroads where scientific innovation, patient empowerment and economic imperatives intersect. The ascent of targeted immunotherapies and digital health initiatives is redefining clinical standards, while evolving tariff structures and payer expectations impose new constraints on cost and access. By integrating these forces into cohesive strategies-grounded in granular segmentation, region-specific intelligence and forward-looking company analyses-stakeholders can navigate uncertainty and capitalize on high-value opportunities.

Success in this market will hinge on the ability to connect clinical differentiation with demonstrable economic value, supported by real-world evidence and flexible commercial constructs. A nuanced appreciation of regional variations and supply chain dynamics will further enhance resilience against policy shifts and competitive incursions. Ultimately, organizations that adopt a holistic, patient-centric mindset while preserving operational agility will emerge as leaders in the next chapter of eczema care.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Phototherapy
    • Systemic
      • Biologics
      • Janus Kinase Inhibitors
    • Topical
      • OTC
        • Anti-Itch Lotions
        • Barrier Repair Creams
        • Emollients
      • Prescription
        • Calcineurin Inhibitors
        • Corticosteroids
        • Pde4 Inhibitors
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Product Type
    • OTC
    • Prescription
  • Formulation
    • Creams
    • Gels
    • Lotions
    • Ointments
  • End User
    • Adult
    • Pediatric
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Sanofi S.A.
  • Regeneron Pharmaceuticals, Inc.
  • AbbVie Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Johnson & Johnson
  • LEO Pharma A/S
  • Galderma S.A.
  • Viatris Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Eczema Therapeutics Market, by Treatment Type
8.1. Introduction
8.2. Phototherapy
8.3. Systemic
8.3.1. Biologics
8.3.2. Janus Kinase Inhibitors
8.4. Topical
8.4.1. OTC
8.4.1.1. Anti-Itch Lotions
8.4.1.2. Barrier Repair Creams
8.4.1.3. Emollients
8.4.2. Prescription
8.4.2.1. Calcineurin Inhibitors
8.4.2.2. Corticosteroids
8.4.2.3. Pde4 Inhibitors
9. Eczema Therapeutics Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Eczema Therapeutics Market, by Product Type
10.1. Introduction
10.2. OTC
10.3. Prescription
11. Eczema Therapeutics Market, by Formulation
11.1. Introduction
11.2. Creams
11.3. Gels
11.4. Lotions
11.5. Ointments
12. Eczema Therapeutics Market, by End User
12.1. Introduction
12.2. Adult
12.3. Pediatric
13. Americas Eczema Therapeutics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Eczema Therapeutics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Eczema Therapeutics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Sanofi S.A.
16.3.2. Regeneron Pharmaceuticals, Inc.
16.3.3. AbbVie Inc.
16.3.4. Pfizer Inc.
16.3.5. Eli Lilly and Company
16.3.6. Novartis AG
16.3.7. Johnson & Johnson
16.3.8. LEO Pharma a/S
16.3.9. Galderma S.A.
16.3.10. Viatris Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ECZEMA THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. ECZEMA THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. ECZEMA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ECZEMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ECZEMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ECZEMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY ANTI-ITCH LOTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY BARRIER REPAIR CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY EMOLLIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY LOTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ECZEMA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ECZEMA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 59. CANADA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 60. CANADA ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 61. CANADA ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 62. CANADA ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 63. CANADA ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 64. CANADA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. CANADA ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 66. CANADA ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 67. CANADA ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. MEXICO ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 69. MEXICO ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 70. MEXICO ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 71. MEXICO ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 72. MEXICO ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 73. MEXICO ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. MEXICO ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 75. MEXICO ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 76. MEXICO ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 115. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 116. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 117. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 118. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 119. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 121. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 122. GERMANY ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. FRANCE ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 124. FRANCE ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 125. FRANCE ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 126. FRANCE ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 127. FRANCE ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 128. FRANCE ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. FRANCE ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 130. FRANCE ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 131. FRANCE ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. ITALY ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 142. ITALY ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 143. ITALY ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 144. ITALY ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 145. ITALY ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 146. ITALY ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. ITALY ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 148. ITALY ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 149. ITALY ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. SPAIN ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 151. SPAIN ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 152. SPAIN ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 153. SPAIN ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 154. SPAIN ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 155. SPAIN ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. SPAIN ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 157. SPAIN ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 158. SPAIN ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. SAUDI ARABIA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. SOUTH AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 178. SOUTH AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. DENMARK ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 187. DENMARK ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 188. DENMARK ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 189. DENMARK ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 190. DENMARK ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 191. DENMARK ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. DENMARK ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 193. DENMARK ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 194. DENMARK ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. QATAR ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 205. QATAR ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 206. QATAR ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 207. QATAR ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 208. QATAR ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 209. QATAR ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. QATAR ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 211. QATAR ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 212. QATAR ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. FINLAND ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 214. FINLAND ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 215. FINLAND ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 216. FINLAND ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 217. FINLAND ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 218. FINLAND ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. FINLAND ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 220. FINLAND ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 221. FINLAND ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. SWEDEN ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 223. SWEDEN ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 224. SWEDEN ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. NIGERIA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. EGYPT ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 241. EGYPT ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 242. EGYPT ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 243. EGYPT ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 244. EGYPT ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 245. EGYPT ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. EGYPT ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 247. EGYPT ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 248. EGYPT ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. TURKEY ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 250. TURKEY ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 251. TURKEY ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 252. TURKEY ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 253. TURKEY ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 254. TURKEY ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. TURKEY ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 256. TURKEY ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 257. TURKEY ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. ISRAEL ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 259. ISRAEL ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 260. ISRAEL ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. NORWAY ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 268. NORWAY ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 269. NORWAY ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 270. NORWAY ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 271. NORWAY ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 272. NORWAY ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. NORWAY ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 274. NORWAY ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 275. NORWAY ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. POLAND ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 277. POLAND ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 278. POLAND ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 279. POLAND ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 280. POLAND ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 281. POLAND ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. POLAND ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 283. POLAND ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 284. POLAND ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 285. SWITZERLAND ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 286. SWITZERLAND ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 287. SWITZERLAND ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 288. SWITZERLAND ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 295. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 296. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC ECZEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 304. CHINA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 305. CHINA ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 306. CHINA ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 307. CHINA ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 308. CHINA ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 309. CHINA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 310. CHINA ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 311. CHINA ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 312. CHINA ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 313. INDIA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 314. INDIA ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 315. INDIA ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 316. INDIA ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 317. INDIA ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 318. INDIA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 319. INDIA ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 320. INDIA ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 321. INDIA ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 322. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 323. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 324. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 325. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 326. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 327. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 328. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 329. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 330. JAPAN ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 331. AUSTRALIA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 332. AUSTRALIA ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 333. AUSTRALIA ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 334. AUSTRALIA ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 335. AUSTRALIA ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 336. AUSTRALIA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 337. AUSTRALIA ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 338. AUSTRALIA ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 339. AUSTRALIA ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 340. SOUTH KOREA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 341. SOUTH KOREA ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 342. SOUTH KOREA ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 343. SOUTH KOREA ECZEMA THERAPEUTICS MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 344. SOUTH KOREA ECZEMA THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 345. SOUTH KOREA ECZEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 346. SOUTH KOREA ECZEMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 347. SOUTH KOREA ECZEMA THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 348. SOUTH KOREA ECZEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 349. INDONESIA ECZEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 350. INDONESIA ECZEMA THERAPEUTICS MARKET SIZE, BY SYSTEMIC, 2018-2030 (USD MILLION)
TABLE 351. INDONESIA ECZEMA THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 352. INDONESIA ECZEMA THERAPEUTICS MARKET SIZE,

Companies Mentioned

The companies profiled in this Eczema Therapeutics market report include:
  • Sanofi S.A.
  • Regeneron Pharmaceuticals, Inc.
  • AbbVie Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Johnson & Johnson
  • LEO Pharma A/S
  • Galderma S.A.
  • Viatris Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 8.24 Billion
Forecasted Market Value ( USD ) by 2030 $ 13.04 Billion
Compound Annual Growth Rate9.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Eczema Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Eczema Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 186 Pages
  • Global
From
Seborrheic Eczema - Pipeline Insight, 2025 - Product Image

Seborrheic Eczema - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Atopic Dermatitis - Pipeline Insight, 2025 - Product Image

Atopic Dermatitis - Pipeline Insight, 2025

  • Clinical Trials
  • 280 Pages
  • Global
From
Atopic Dermatitis Drugs Market by Drug Class, Route Of Administration, Mode Of Administration, Distribution Channel, Patient Age Group - Global Forecast to 2030 - Product Image

Atopic Dermatitis Drugs Market by Drug Class, Route Of Administration, Mode Of Administration, Distribution Channel, Patient Age Group - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Atopic Dermatitis Drugs - Global Strategic Business Report - Product Image

Atopic Dermatitis Drugs - Global Strategic Business Report

  • Report
  • 179 Pages
  • Global
From

About the Eczema Drug Market

The Eczema Drug market is a subset of the Dermatological Drugs market, which includes medications used to treat skin conditions. Eczema drugs are used to treat the symptoms of eczema, a chronic skin condition characterized by red, itchy, and inflamed skin. These drugs are typically topical creams, ointments, and lotions, and may contain corticosteroids, calcineurin inhibitors, and other active ingredients. In addition to treating the symptoms of eczema, these drugs may also help to reduce the risk of infection and improve the overall quality of life for those affected by the condition. Some companies in the Eczema Drug market include GlaxoSmithKline, Pfizer, Novartis, Sanofi, and Mylan. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.